

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/701,455	11/06/2003	Eric B. Stenzel	12013/48301	8547
23838	7590 09/23/2005		EXAMINER	
KENYON & KENYON			GHERBI, SUZETTE JAIME J	
1500 K STRE SUITE 700	EET NW		ART UNIT	PAPER NUMBER
WASHINGTON, DC 20005			3738	
			, D. ME 14. II ED 00/02/000	_

Please find below and/or attached an Office communication concerning this application or proceeding.

	· .	TATA				
	Application No.	Applicant(s)				
Office Action Summary	10/701,455	STENZEL, ERIC B.				
Office Action Summary	Examiner	Art Unit				
The MAN INC BATT of this commission of	Suzette J. Gherbi	3738				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 30 Ju	ıne 2005.					
	action is non-final.					
3) Since this application is in condition for allowar						
Disposition of Claims						
4)	vn from consideration.					
Application Papers	•					
9)☐ The specification is objected to by the Examine	г.					
•	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the	* ' '					
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex						
Priority under 35 U.S.C. § 119		•				
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)	» —	(070, 442)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 6/9/05 & 6/30/05. 	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:					

DETAILED ACTION

1. Applicant's amendment dated June 6/30/05 has been received in application serial number 10/701,455. claims 2-3, 6-8, 18, and 22 have been canceled.

Claim Rejections - 35 USC § 112

- 2. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 3. Claims 1, 4-5, 9-17, 19-21, 23-27 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.
- 4. In particular claims 1, 12 and 17 recite subject matter that is not described in the specification or drawings specifically there is NO mention in the specification about a <u>first set</u> of pellets <u>and a second set</u> of pellets contained <u>upon a structure</u>. The specification describes <u>individual</u> pellets with <u>individual</u> coatings upon a structure in single form (being thick or thin) but nowhere does the specification discloses the arrangement of these pellets as a first set and second set upon <u>a structure</u> as claimed.

Applicant has stated in the remarks section that the claimed subject matter is described in several places in the specification...for example paragraph 40 on page 13, but it has been found that these passages merely describes individual pellets being made of various sizes depending upon the composition. It does not describe depositing a set of second pellets on the structure at a second site.

Drawings

- 5. The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the second set of pellets deposited on the structure at a second site must be shown or the feature(s) canceled from the claim(s). Please note the new matter rejection above.
- 6. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an

application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

Claim Rejections - 35 USC § 103

- 7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 8. Claims 1, 4, 9-10, 12-16, 24-27 are rejected under 35 U.S.C. 103(a) as being obvious over Stoll 6,849,089. Stoll discloses the invention as claimed noting figures 6 and 7 comprising: A medical structure (2); a set of first coated pellets (the coating is 5""), each of the first coated pellets containing at least one first therapeutic composition (the round sphere micro-capsules equate to the claimed pellet. The first material 4 is the first therapeutic substance) the set of first coated pellets_deposited on the structure (the claimed structure equates to element 2 main body) at a first site for controlled delivery of at least one first therapeutic composition (the first site can be interpreted as the first microspore or as the first layer upon the structure 2 as shown in figures 6 and 8) and a set of second coated pellets, (the second set of

pellets can be interpreted as the adjacent pellets seen in figure 7 or as the second layer of pellets as shown in figures 6 and 8) each of the second coated pellets containing at least one second therapeutic composition (the second therapeutic composition is contained in the micro-sphere in a separate second compartment. The claim does not require a different second therapeutic substance), the set of second coated pellets deposited on the structure at a second site (as described above a second site can be interpreted broadly) for controlled delivery of the at least one second therapeutic composition to a desired location within the body; wherein each of said first coated pellets is covered with a first coating and each of said second coated pellets is covered with a second coating (they are both individually coated with polymers and the claim does not require different coatings); wherein each of the first coated pellets contains a substance in addition to the first therapeutic composition (this can be interpreted broadly because a "substance in addition to the first therapeutic composition" can simply be the make-up of the degradable polymer);

However Stoll does not specify: wherein the first coating is thinner than the second coatingsuch that each of the first coated pellets is substantially the same size as each of the second coated pellets. It would have been obvious to one having ordinary skill in the art at the time the invention was made that Stoll's invention contemplates to varying or modifying the thinness or thickness of the coatings of the micro-spheres/pellets in order to control the release rate of the agent(as indicated in col. 13, lines 18-33) and is deemed a design modification.

Application/Control Number: 10/701,455

Art Unit: 3738

Page 6

9. Claims 5, 11, 17, 19-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Stoll in view of Bennett et al. 6,339,130. Stoll has been disclosed above however Stolls adhesive is not described. Bennett et al. teaches that adhesives for use with prosthetic devices are well known and polymers are known adhesive with curing properties (see abstract and col. 3, lines 12-35). It would have been obvious to one having ordinary skill I the art at the time the invention was made to make the adhesive of Stoll with the claimed properties such as polymers because Bennett et al. teaches that they can be used with a variety of surgical devices. Stoll also does not specify that a plurality of sublayers on the micro-spheres. It would have been obvious to one having ordinary skill I the art at the time the invention was made to add a plurality of sublayers because Stoll does note that a plurality of layers are contemplated (see figure 5) in order to vary the degradation and release rate of the therapeutic compositions.

Response to Arguments

Applicant's arguments filed 6/30/05 have been fully considered but they are not persuasive. Applicant has amended the claims with subject matter not found or described in the specification. Applicant contends that Stoll does not disclose or suggest pellets having different coating thickness. The examiner has pointed out figure 7 where clearly illustrations that the walls (5") have varying wall thicknesses. Applicant contends that that Stoll does not disclose an additional "substance". This terminology is

broad and is being interpreted as <u>any</u> additional material. Therefor the substance in addition to the first therapeutic composition if the make-up of the bio-degradable polymer.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suzette J. Jackson whose work schedule is Monday-Friday 9-6:30 off every other Friday and whose telephone number is 571-272-4751.

The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-

0858.

Súzette J-J Gherbi 19 September 2005